knee osteoarthritis. Osteoarthritis of knee
Conditions
Interventions
Intervention group: piroxicam mesotherapy.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Clinical signs of knee osteoarthritis (based on the clinical criteria of the American College of Rheumatology) Duration of symptoms longer than three months Kellgren–Lawrence grade 2 or 3 (mild to moderate) on radiography within the past month Age 4 to 70 years in both sexes VAS score greater than 3 (Visual Analog Scale Absence of pathological conditions around the knee, such as bursitis and cellulitis Willingness to participate in the study
Exclusion criteria
Exclusion criteria: Any intra-articular or periarticular injection within the past three months Use of NSAIDs for pain relief in the past three days or during the study period History of cancer, diabetes mellitus, rheumatologic and collagen-vascular diseases, and gout Clinical signs of knee effusion, warmth, or redness History of knee trauma History of knee arthroplasty or other surgeries BMI greater than 42 Presence of active radiculopathy, myopathy, or peripheral neuropathy in the lower extremities Pregnancy or breastfeeding Allergy to piroxicam and other NSAIDs Severe gastrointestinal, hepatic, renal, respiratory, neurological, or cardiovascular diseases Severe knee osteoarthritis on radiography (Kellgren–Lawrence grade 4) Any condition associated with a tendency to bleed Use of anticoagulant medications Any serious systemic or local infection (e.g., brucellosis) Inability to complete questionnaires Failure to control pain with standard treatment, injections and acetaminophen
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee pain score in VAS, WOMAC and OKS. Timepoint: before treatment & 2, 4 and 8 weeks after treatment. Method of measurement: VAS, WOMAC and OKS questionnaire and acetaminophen use as analgesic. | — |
Secondary
| Measure | Time frame |
|---|---|
| Function. Timepoint: before treatment, 2,4 and 8 weeks after treatment. Method of measurement: WOMAC and OKS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMitra Pegah
Shiraz University of Medical Sciences
Outcome results
None listed